ClinicalTrials.gg
RecruitingNCT06843304Updated Apr 20, 2025

The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy

An observational study in Diabetic Nephropathy and T2DM, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Chinese PLA General Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.

Planned enrollment
5th of 22
2,000 · median 620
Started
2024
with 5 others
Observational
22 of 75
10 open now
Primary completion
2026-12
later than 19 of 29 live
Registered
62nd of 75
by date
Lead sponsor
4 of 75
Chinese PLA General Hospital

Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 5th largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2024, is one of 22 observational ones, reaches primary completion later than 19 of the 29 other live ones, and was the 62nd registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetic Nephropathies with a site in China, or all of them as a file.
02

Study summary

Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. By integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. Utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. The project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. Ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.

03

Conditions studied

  • Diabetic Nephropathy
  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with type 2 diabetes mellitus and type 2 diabetes mellitus with CKD

Eligibility criteria

T2DM

Inclusion Criteria:

  • Age ≥18 years old, gender is not limited
  • Diagnosed with type 2 diabetes
  • A history of type 2 diabetes for more than 5 years
  • Negative proteinuria
  • Creatinine is normal
  • Good compliance, voluntarily sign

Exclusion Criteria:

  • Incomplete medical records
  • Lack of fundus microvascular examination or new imaging technology examination results data
  • Combined with diseases and tumors

Type 2 diabetes patients undergoing renal

Inclusion Criteria:

  • Age ≥18 years old, gender is not limited
  • Diagnosed with type 2 diabetes
  • Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency)
  • Have undergone renal puncture biopsy and have complete renal pathological diagnosis data
  • Sign informed consent voluntarily

Exclusion Criteria:

  • Gestational diabetes mellitus, special type diabetes mellitus
  • Patients with hereditary kidney disease
  • Combined with autoimmune diseases
  • Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained
  • There were pregnancy plans in the study period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with type 2 diabetes mellitus and type 2 diabetes mellitus with CKD

    Based on the national multi-center diabetic nephropathy cohort built since 2017, and continues to establish prospective diabetes nephropathy whole life cycle cohort. Individuals with type 2 diabetes will be followed up until renal dysfunction occurs and continue to be followed up until the occurrence of renal endpoints. Individuals with diabetic nephropathy of type 2 diabetes will be followed up until the occurrence of renal endpoints.

06

What researchers measure

Primary outcomes

  1. The incidence of complex renal endpoints

    The incidence of complex renal endpoints includes eGFR decreased progressively by more than 30% from baseline, ESRD and all-cause death.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 38 observational studies under Diabetic Nephropathies, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 25. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Feb 24, 2025
StartActual
Jan 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06843304
Responsible party
Xiangmei Chen (Academician/Principal Investigator/ Clinical Professor/Director, Chinese PLA General Hospital) — Principal investigator
First posted
Feb 24, 2025
Start date
Jan 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 20, 2025

Study contacts

Zheyi Dong, MD
Contact
shengdai26@163.com
+86 13810261592

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion